ABSTRACT
Background and Aims: During the SARS COV 2 pandemic, the number of cases of unrecognized diabetes increased in those hospitalized for pneumonia. It has been hypothesized that some forms of diabetes not classified as classic are attributable to SARS COV 2 infection. Method(s): We studied the prevalence of diabetes in those admitted to our Covid Hospital from January 2021 to September 2022. A total of 1200 subjects studied by cross-analysis of hospital discharge forms with diabetes mellitus and final therapy as research item. Result(s): The prevalence of diabetes mellitus was 2.16%. Of the subjects diagnosed with diabetes, 26.9% were not classifiable as type 1 or type 2 and the condition of diabetes mellitus was not previously known. HbA1c values were not statistically (7,86+/-0,95 vs 8,1+/-1,1 p = NS) different among subjects with diabetes and autoimmune markers were not present. Fasting C-peptide levels (ng/ml) were significantly lower (0,8- 0,23 vs 2,36+/-0,8 p < 0.05) in those with not previously known diabetes, 57.2% were discharged on insulin therapy. and continued it after 92- 18 days of follow-up. Conclusion(s): The interrelationship between COVID-19 and diabetes remain uncertain and researchers hope to understand whether Covid-19 causes a new form of diabetes or more simply a stress response that triggers classic diabetes. In our experience those individuals with fasting C-peptide levels lower than usual obeserved in Type 2 diabetic subjects continued insulin theraphy for a limited time. They could be a new entity of diabetes classification but longitudinal data are further required to confirm what we can call DIabCovid.
ABSTRACT
Background and Aims: The COVID emergency has led to a reduction in the volume of care dedicated to people with Type 1 DM. The use of telemedicine can represent a means of protection. Methods: We investigated the role of FGM in 56 subjects with type 1 DM, AGP parameters were taken into consideration in the following periods: 1) October 2020 (start of the second wave in Italy), 2) May 2021 (reduction of hospitalizations due to SARS-Cov2 disease and opening of outpatient facilities) and 3) November 2021 (maintenance of dedicated COVID facilities and outpatient facilities). All subjects (ages 23.4 +/- 11.2) employed the CHO counting technique. Results: The coefficient of variation and the Glucose Management Indicator increased significantly between period 1 and 2 (37.17 vs 42.30 P = 0.03 and 8.08 vs 9.1 P = 0.005 respectively). In the second period, all the subjects were called back to the center to be re-evaluated. The opposite trend was observed for CVandGMI from the second period to date (current CV and GMI 33.10 P = 0.0002 and 7.8 P = 0.0004). TIR, TAR, TBR were not significantly different between period 1 and 2 they were significantly different from the second period to date (TIR2 55.24 vs TIR 3 65.56 P = 0.001- TAR2 40.39 vs TAR3 27.59 P = 0.001). Conclusions: Remote data control is a fundamental means of identifying those at risk of worsening glycemic control in an exponential manner and to re-propose structured training to guarantee the benefits obtained in the period prior to the pandemic.
ABSTRACT
Background and Aims: Connecting in-person with patients is challenging during COVID, potentially undermining the frequency and quality of consultations with health care professionals (HCPs). Telemedicine offers a way to support patient provider connectivity. Methods: Survey data was collected from 22 HCPs from 20 institutions who then participated in one of four virtual meetings to share telemedicine insights using the professional version of One Touch Reveal® (OTR Pro) ecosystem. Results: Remote consultations increased 46% in these institutions during COVID, divided 52% and 48% between patients with type 1 and type 2 diabetes. Methods included telephone (60%), email (19%), video (10%), texting (3%), or combinations (8%). HCPs reviewed OTR Pro data during (45%) or before (25%) consultations, every 3 months (20%) or every 2 weeks (5%). 55% of HCPs said going forward, OTR Pro would become their standard of care, 30% for current or new patients, 10%during face-to-face visits and only 5% returning to face-to-face consultations without OTR Pro. For managing patients, HCPs ranked ''allows me to make treatment/therapy decisions,'' ''helps me schedule consultations/ reminders,'' ''access 24/7 to status of my patients,'' as the top 3 benefits of OTR Pro. 95% of HCPs agreed OTR Pro identified patterns, trends and trouble spots for more meaningful conversations with patients, facilitating clinical practice during COVID. Conclusions: The One Touch Reveal® ecosystem supported telemedicine during the pandemic and will continue to play a valuable role beyond the pandemic.